Iambic Therapeutics, a San Diego company that uses artificial intelligence to design medicines, registered for a US initial public offering this week, in one of the first tests of whether public investors will pay for AI drug discovery.
The company, founded in 2019, plans to sell 9.375 million common shares at an expected price of $15 to $17 each, raising roughly $141 million to $159 million, according to its filing with the Securities and Exchange Commission.
The cap table reads like a crossover between Silicon Valley and biotech. Nvidia is a shareholder. So are Catalio Capital Management, Nexus Venture Partners, Coatue, and the health-care investment arm of the Qatar Investment Authority. Since launching, Iambic has raised $461.8 million from technology and health-care backers.
Iambic describes itself as a clinical-stage life-sciences and technology company that applies machine learning to crafting new medicines. It plans to channel the IPO proceeds into three cancer programs still in early development.
JPMorgan, Jefferies, Bank of America and Citigroup are leading the underwriting. The company plans to list on the Nasdaq Global Select Market under the ticker IAM.
The filing describes a company that has moved its computational platform from promise toward the clinic. Its machine-learning models aim to predict which molecules will bind to a target protein before expensive lab work begins, the idea being to compress the years and cost that separate a concept from a medicine.
Nvidia’s stake places it among a group of investors that spans technology and health care. Catalio Capital Management and Nexus Venture Partners are life-science specialists; Coatue is a technology investor; and the Qatar Investment Authority’s health-care arm brings sovereign capital. The mix reflects how AI drug discovery now draws money from both worlds.
The offering is a bet that AI drug discovery has moved from promise to something investors can underwrite. The field attracted enormous sums in private markets, but public-market evidence has been thinner, and biotech investors have been selective after a bruising stretch for early-stage companies.
Iambic’s filing lists partnerships that include Nvidia and Lambda, an AI cloud provider, a sign that its computing needs tie it to the same infrastructure boom that has powered the broader AI trade. Drug discovery is, at bottom, a computing problem: screening millions of molecules and simulating how they bind to proteins.
The presence of Nvidia on the shareholder list is notable but increasingly common. The chipmaker has spread small investments across the AI ecosystem – data-center builders, cloud providers and drug-discovery firms – making itself a stakeholder in nearly every corner of the market that buys its chips.
For Iambic, the IPO is a fundraising that has been years in the making. Like many AI-first biotechs, it has relied on private rounds to fund expensive research, and the public market offers a deeper pool as it advances its cancer programs toward the clinic.
The timing is uneasy. AI stocks sold off sharply on Thursday after a report raised questions about OpenAI’s revenue, and biotech listings have been choppy all year. A debut in that climate will test whether investors can separate the science from the market’s mood.
Iambic’s pitch leans on the science. It uses computational models to predict which drug candidates will work before committing to costly lab and clinical work, a promise that, if it holds, would cut the time and money required to bring a medicine to patients.
That promise is exactly what makes the sector hard to value. The companies are cheap to start and expensive to prove, and the distance between a promising model and an approved drug is measured in years and hundreds of millions of dollars. Public investors are being asked to buy that distance.
Nvidia’s involvement cuts both ways. It lends credibility to the technology and signals access to the computing power the company needs. It also means Iambic’s story is now partly a story about AI infrastructure, a narrative that has made investors money and then taken it back, sometimes in the same week.
Public markets have been cautious about the category. A handful of AI drug companies listed in recent years to mixed results, and investors have learned that a strong computational platform does not guarantee a strong drug. Iambic’s debut will be read as a signal for the rest of the field.
For now, the filing is a prospectus, not a verdict. The price range is set, the underwriters are in place, and the order book will tell whether the market’s appetite for AI science survives contact with a real, early-stage, money-losing biotech.
The bankers leading the deal will watch the order book closely. A successful debut would open the door for the dozen or so other AI drug firms waiting in the wings; a stumble would send them back to private markets, and keep the sector’s public test on hold a while longer.
